Wednesday, June 26, 2013

Best sequence for optimal targeted mRCC therapy remains elusive

The use of targeted therapies for metastatic renal cell carcinoma could see patients surviving in excess of 2 years, suggest findings from the Institut Gustave Roussy in Paris, France.

via Med Wire News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)